The uroprotection of mesna on cyclophosphamide cystitis in rats. Its consequences on behaviour and brain activities.
We studied the uroprotective effect of mesna, at doses of 40-300 mg/kg/i.p., in single or fractioned injections, on the development of cyclophosphamide (CP, 100 mg/kg/i.p.) cystitis in rats. The study concerns the histological, behavioural and nervous aspects of the disease. The specific effects of mesna, when injected alone, have also been considered. The mesna itself does not have specific deleterious effects, except at a dose of 300 mg/kg which provokes a moderate vesical inflammation although without consequence on the animal's behaviour. Mesna offers good protection against CP cystitis for only certain posologies. The uroprotective effects of mesna reach maxima at doses of 40-100 mg/kg and for fractioned injections given over the entire time frame of the urinary toxic release. The uroprotective effects of other posologies are only partial. The nervous activities were studied through the expression of Fos protein. The repetitive intraperitoneal injection of mesna induced a spinal activity and a preferential contralateral activity of the trigemino/reticular areas of the brainstem spinal cord junction--an effect which was reduced in the presence of CP. The prevention of cystitis by mesna was accompanied only by a reduction in spinal Fos activity, the supraspinal activities remaining high and in strict relationship with the vagal afferent activity. In conclusion, the uroprotective effect of mesna, which requires appropriate posologies, has led to the confirmation of the spinal actions of the CP cystitis, probably via the pelvic nerve, but did not allow a clear distinction between the consequences of the systemic (vagal) and local (spinal, pelvic) actions of CP at supraspinal level.
Menétrey
D
D
Unité 161 de l'Inserm, Paris, France. menetrey@broca.inserm.fr
Bon
K
K
Michiels
J F
JF
Lantéri-Minet
M
M
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D003520:Cyclophosphamide; D003556:Cystitis / Q000139:chemically induced / Q000517:prevention & control*; D007700:Kinetics; D008297:Male; D015080:Mesna / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D020011:Protective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
D020011:Protective Agents; D003520:Cyclophosphamide; D015080:Mesna